Ruosen Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruosen Xie has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Shaoqin Gong
Wisconsin Institute of Discovery, University of Wisconsin-Madison, Madison, USA
21 shared publications Yuyuan Wang
Department of Biomedical Engineering and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA; Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, 53715, USA
14 shared publicationsGuojun Chen
Department of Materials Science and Engineering, and Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
7 shared publicationsMingzhou Ye
Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
5 shared publicationsYi Zhao
Department of Ophthalmology and Visual Sciences, University of Wisconsin–Madison, Madison, USA
5 shared publicationsBowen Wang
Division of Surgical Sciences, Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
4 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 66, 692-708
Glycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections
The antimicrobial resistance (AMR) crisis necessitates strategies to revitalize existing antibiotics against multidrug-resistant pathogens. While cationic antimicrobial polymers can disrupt bacterial membranes, their clinical translation is hindered by host toxicity. Here we report a hierarchical, stimuli-responsive nanomedicine designed on principles of safety, specificity, switchability, and synergy. We synthesized phenylboronic ester-caged biodegradable polymers shielded by functional polysaccharide shells. These nanoparticles remain inert during circulation but selectively activate within infection microenvironments. Upon activation, the exposed cationic polymer physically compromises bacterial membranes, enabling the entry of co-delivered antibiotics such as rifampicin into Gram-positive, Gram-negative, mycobacterial, and biofilm-embedded pathogens. Our research led to the discovery of glycans that significantly improve therapeutic outcomes. We found that different glycans exhibited distinct effects in various tissues and conditions: chondroitin sulfate effectively targeted CD44-abundant infectious niches, enabling precise localization and enhanced therapeutic efficacy, whereas levan uniquely stimulated macrophage oxidative bursts, promoting intracellular pathogen clearance. By leveraging these distinct biological interactions, our platform overcomes the physical and biological barriers of AMR, offering a universal strategy to treat diverse, multidrug-resistant infections.
- 1 December 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 66, 692-708
Open AccessGlycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections
The antimicrobial resistance (AMR) crisis necessitates strategies to revitalize existing antibiotics against multidrug-resistant pathogens. While cationic antimicrobial polymers can disrupt bacterial membranes, their clinical translation is hindered by host toxicity. Here we report a hierarchical, stimuli-responsive nanomedicine designed on principles of safety, specificity, switchability, and synergy. We synthesized phenylboronic ester-caged biodegradable polymers shielded by functional polysaccharide shells. These nanoparticles remain inert during circulation but selectively activate within infection microenvironments. Upon activation, the exposed cationic polymer physically compromises bacterial membranes, enabling the entry of co-delivered antibiotics such as rifampicin into Gram-positive, Gram-negative, mycobacterial, and biofilm-embedded pathogens. Our research led to the discovery of glycans that significantly improve therapeutic outcomes. We found that different glycans exhibited distinct effects in various tissues and conditions: chondroitin sulfate effectively targeted CD44-abundant infectious niches, enabling precise localization and enhanced therapeutic efficacy, whereas levan uniquely stimulated macrophage oxidative bursts, promoting intracellular pathogen clearance. By leveraging these distinct biological interactions, our platform overcomes the physical and biological barriers of AMR, offering a universal strategy to treat diverse, multidrug-resistant infections.
- Open Access
- 13 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8086
Genome-wide CRISPR screening identifies cellular factors controlling nonviral genome editing efficiency
- 13 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8086
Open AccessGenome-wide CRISPR screening identifies cellular factors controlling nonviral genome editing efficiency
- Open Access
- 29 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 729
Photodynamic Therapy for Atherosclerosis: Past, Present, and Future
This review paper examines the evolution of photodynamic therapy (PDT) as a novel, minimally invasive strategy for treating atherosclerosis, a leading global health concern. Atherosclerosis is characterized by the accumulation of lipids and inflammation within arterial walls, leading to significant morbidity and mortality through cardiovascular diseases such as myocardial infarction and stroke. Traditional therapeutic approaches have primarily focused on modulating risk factors such as hypertension and hyperlipidemia, with emerging evidence highlighting the pivotal role of inflammation. PDT, leveraging a photosensitizer, specific-wavelength light, and oxygen, offers targeted treatment by inducing cell death in diseased tissues while sparing healthy ones. This specificity, combined with advancements in nanoparticle technology for improved delivery, positions PDT as a promising alternative to traditional interventions. The review explores the mechanistic basis of PDT, its efficacy in preclinical studies, and the potential for enhancing plaque stability and reducing macrophage density within plaques. It also addresses the need for further research to optimize treatment parameters, mitigate adverse effects, and validate long-term outcomes. By detailing past developments, current progress, and future directions, this paper aims to highlight PDT’s potential in revolutionizing atherosclerosis treatment, bridging the gap from experimental research to clinical application.
- 29 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 729
Open AccessPhotodynamic Therapy for Atherosclerosis: Past, Present, and Future
This review paper examines the evolution of photodynamic therapy (PDT) as a novel, minimally invasive strategy for treating atherosclerosis, a leading global health concern. Atherosclerosis is characterized by the accumulation of lipids and inflammation within arterial walls, leading to significant morbidity and mortality through cardiovascular diseases such as myocardial infarction and stroke. Traditional therapeutic approaches have primarily focused on modulating risk factors such as hypertension and hyperlipidemia, with emerging evidence highlighting the pivotal role of inflammation. PDT, leveraging a photosensitizer, specific-wavelength light, and oxygen, offers targeted treatment by inducing cell death in diseased tissues while sparing healthy ones. This specificity, combined with advancements in nanoparticle technology for improved delivery, positions PDT as a promising alternative to traditional interventions. The review explores the mechanistic basis of PDT, its efficacy in preclinical studies, and the potential for enhancing plaque stability and reducing macrophage density within plaques. It also addresses the need for further research to optimize treatment parameters, mitigate adverse effects, and validate long-term outcomes. By detailing past developments, current progress, and future directions, this paper aims to highlight PDT’s potential in revolutionizing atherosclerosis treatment, bridging the gap from experimental research to clinical application.
- Top Cited Papers
- 17 April 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (7) , 1032-1043
Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections
The increasing prevalence of antimicrobial resistance in Staphylococcus aureus necessitates alternative therapeutic approaches. Neutrophils play a crucial role in the fight against S. aureus but suffer from deficiencies in function leading to increased infection. Here we report a nanoparticle-mediated immunotherapy aimed at potentiating neutrophils to eliminate S. aureus. The nanoparticles consist of naftifine, haemoglobin (Hb) and a red blood cell membrane coating. Naftifine disrupts staphyloxanthin biosynthesis, Hb reduces bacterial hydrogen sulfide levels and the red blood cell membrane modifies bacterial lipid composition. Collectively, the nanoparticles can sensitize S. aureus to host oxidant killing. Furthermore, in the infectious microenvironment, Hb triggers lipid peroxidation in S. aureus, promoting neutrophil chemotaxis. Oxygen supplied by Hb can also significantly enhance the bactericidal capability of the recruited neutrophils by restoring neutrophil respiratory burst via hypoxia relief. This multimodal nanoimmunotherapy demonstrates excellent therapeutic efficacy in treating antimicrobial-resistant S. aureus persisters, biofilms and S. aureus-induced infection in mice.
- 17 April 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (7) , 1032-1043
Top Cited PapersMultimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections
The increasing prevalence of antimicrobial resistance in Staphylococcus aureus necessitates alternative therapeutic approaches. Neutrophils play a crucial role in the fight against S. aureus but suffer from deficiencies in function leading to increased infection. Here we report a nanoparticle-mediated immunotherapy aimed at potentiating neutrophils to eliminate S. aureus. The nanoparticles consist of naftifine, haemoglobin (Hb) and a red blood cell membrane coating. Naftifine disrupts staphyloxanthin biosynthesis, Hb reduces bacterial hydrogen sulfide levels and the red blood cell membrane modifies bacterial lipid composition. Collectively, the nanoparticles can sensitize S. aureus to host oxidant killing. Furthermore, in the infectious microenvironment, Hb triggers lipid peroxidation in S. aureus, promoting neutrophil chemotaxis. Oxygen supplied by Hb can also significantly enhance the bactericidal capability of the recruited neutrophils by restoring neutrophil respiratory burst via hypoxia relief. This multimodal nanoimmunotherapy demonstrates excellent therapeutic efficacy in treating antimicrobial-resistant S. aureus persisters, biofilms and S. aureus-induced infection in mice.
- 13 July 2023
- Published by Elsevier in Biomaterials
- Vol. 301, 122245
Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
- 13 July 2023
- Published by Elsevier in Biomaterials
- Vol. 301, 122245
Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
- 17 February 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (8) , 10464-10476
Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles
Genome editing mediated by the CRISPR-Cas system holds great promise for the treatment of genetic diseases. However, safe and efficient in vivo delivery of CRISPR genome editing machinery remains a challenge. Here, we report a lipopeptide-based nanoparticle (LNP) that can efficiently deliver the CRISPR Cas9/sgRNA ribonucleoprotein (RNP) and enable efficient genome editing both in vitro and in vivo. An artificial lipopeptide, GD-LP, was constructed by linking a hydrophilic guanidinium-rich head to an oleic acid-based hydrophobic tail via a disulfide bond. LNP formed by the self-assembly of GD-LP can easily form a complex with RNP with a loading content of up to 20 wt %. The resulting RNP-LNP nanocomplex led to 72.6% gene editing efficiency in GFP-HEK cells with negligible cytotoxicity. The LNP also showed significantly higher transfection efficiencies than Lipofectamine 2000 for the delivery of mRNA in NIH 3T3 and RAW 264.7 and the delivery of plasmid DNA in B78 cells. In vivo studies showed that intramuscular injection of the RNP-LNP nanocomplex in Ai14 mice induced efficient gene editing in muscular tissues. Moreover, the delivery of Cas9 RNP and donor DNA by LNP (i.e., RNP/ssODN-LNP nanocomplex) restored dystrophin expression, reduced skeletal muscle fibrosis, and significantly improved muscle strength in a Duchenne muscular dystrophy (DMD) mouse model.
- 17 February 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (8) , 10464-10476
Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles
Genome editing mediated by the CRISPR-Cas system holds great promise for the treatment of genetic diseases. However, safe and efficient in vivo delivery of CRISPR genome editing machinery remains a challenge. Here, we report a lipopeptide-based nanoparticle (LNP) that can efficiently deliver the CRISPR Cas9/sgRNA ribonucleoprotein (RNP) and enable efficient genome editing both in vitro and in vivo. An artificial lipopeptide, GD-LP, was constructed by linking a hydrophilic guanidinium-rich head to an oleic acid-based hydrophobic tail via a disulfide bond. LNP formed by the self-assembly of GD-LP can easily form a complex with RNP with a loading content of up to 20 wt %. The resulting RNP-LNP nanocomplex led to 72.6% gene editing efficiency in GFP-HEK cells with negligible cytotoxicity. The LNP also showed significantly higher transfection efficiencies than Lipofectamine 2000 for the delivery of mRNA in NIH 3T3 and RAW 264.7 and the delivery of plasmid DNA in B78 cells. In vivo studies showed that intramuscular injection of the RNP-LNP nanocomplex in Ai14 mice induced efficient gene editing in muscular tissues. Moreover, the delivery of Cas9 RNP and donor DNA by LNP (i.e., RNP/ssODN-LNP nanocomplex) restored dystrophin expression, reduced skeletal muscle fibrosis, and significantly improved muscle strength in a Duchenne muscular dystrophy (DMD) mouse model.
- 13 December 2022
- Published by Elsevier in Biomaterials
- Vol. 293, 121959
Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins
- 13 December 2022
- Published by Elsevier in Biomaterials
- Vol. 293, 121959
Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins
- Open Access
- 23 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade
Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this effect may be limited because RT does not fully optimize tumor antigen presentation or fully overcome suppressive mechanisms in the tumor-immune microenvironment. To overcome this, we develop a multifunctional nanoparticle composed of polylysine, iron oxide, and CpG (PIC) to increase tumor antigen presentation, increase the ratio of M1:M2 tumor-associated macrophages, and enhance stimulation of a type I interferon response in conjunction with RT. In syngeneic immunologically “cold” murine tumor models, the combination of RT, PIC, and ICB significantly improves tumor response and overall survival resulting in cure of many mice and consistent activation of tumor-specific immune memory. Combining RT with PIC to elicit a robust in situ vaccine effect presents a simple and readily translatable strategy to potentiate adaptive anti-tumor immunity and augment response to ICB or potentially other immunotherapies.
- 23 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessMultifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade
Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this effect may be limited because RT does not fully optimize tumor antigen presentation or fully overcome suppressive mechanisms in the tumor-immune microenvironment. To overcome this, we develop a multifunctional nanoparticle composed of polylysine, iron oxide, and CpG (PIC) to increase tumor antigen presentation, increase the ratio of M1:M2 tumor-associated macrophages, and enhance stimulation of a type I interferon response in conjunction with RT. In syngeneic immunologically “cold” murine tumor models, the combination of RT, PIC, and ICB significantly improves tumor response and overall survival resulting in cure of many mice and consistent activation of tumor-specific immune memory. Combining RT with PIC to elicit a robust in situ vaccine effect presents a simple and readily translatable strategy to potentiate adaptive anti-tumor immunity and augment response to ICB or potentially other immunotherapies.
- Top Cited Papers
- 6 June 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (8) , 880-890
NAD(H)-loaded nanoparticles for efficient sepsis therapy via modulating immune and vascular homeostasis
Sepsis is a life-threatening organ dysfunction responsible for nearly 270,000 deaths annually in the United States alone. Nicotinamide adenine dinucleotide (NAD+), an immunomodulator, can potentially treat sepsis; however, clinical application of NAD+ is hindered by its inability to be directly taken up by cells. To address this challenge, a family of nanoparticles (NPs) loaded with either NAD+ or the reduced form of NAD+ (NADH), hereafter NAD(H)-loaded NPs, were engineered to enable direct cellular transport and replenishment of NAD(H). The NAD(H)-loaded NPs improved cellular energy supply, suppressed inflammation and prevented inflammation-induced cell pyroptosis and apoptosis. Therefore, the NPs can help maintain immune homoeostasis and vascular function, two key factors in the pathogenesis of sepsis. The NAD(H)-loaded NPs demonstrated excellent therapeutic efficacies in treating endotoxemia and multidrug-resistant pathogen-induced bacteremia. In addition, the NAD(H)-loaded NPs prevented caecal ligation and puncture-induced multiorgan injury and improved outcomes of secondary Pseudomonas aeruginosa infections following caecal ligation and puncture, thus potentially leading to a highly innovative and translational approach to treat sepsis efficiently and safely.
- 6 June 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (8) , 880-890
Top Cited PapersNAD(H)-loaded nanoparticles for efficient sepsis therapy via modulating immune and vascular homeostasis
Sepsis is a life-threatening organ dysfunction responsible for nearly 270,000 deaths annually in the United States alone. Nicotinamide adenine dinucleotide (NAD+), an immunomodulator, can potentially treat sepsis; however, clinical application of NAD+ is hindered by its inability to be directly taken up by cells. To address this challenge, a family of nanoparticles (NPs) loaded with either NAD+ or the reduced form of NAD+ (NADH), hereafter NAD(H)-loaded NPs, were engineered to enable direct cellular transport and replenishment of NAD(H). The NAD(H)-loaded NPs improved cellular energy supply, suppressed inflammation and prevented inflammation-induced cell pyroptosis and apoptosis. Therefore, the NPs can help maintain immune homoeostasis and vascular function, two key factors in the pathogenesis of sepsis. The NAD(H)-loaded NPs demonstrated excellent therapeutic efficacies in treating endotoxemia and multidrug-resistant pathogen-induced bacteremia. In addition, the NAD(H)-loaded NPs prevented caecal ligation and puncture-induced multiorgan injury and improved outcomes of secondary Pseudomonas aeruginosa infections following caecal ligation and puncture, thus potentially leading to a highly innovative and translational approach to treat sepsis efficiently and safely.
- 28 April 2022
- Published by Wiley in Advanced Materials
- Vol. 34 (23) , 2110618-e2110618
pH‐Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA
Clustered regularly interspaced short palindromic repeat (CRISPR)‐associated protein 9 (Cas9) may offer new therapeutics for genetic diseases through gene disruption via nonhomologous end joining (NHEJ) or gene correction via homology‐directed repair (HDR). However, clinical translation of CRISPR technology is limited by the lack of safe and efficient delivery systems. Here, facilely fabricated pH‐responsive polymer nanoparticles capable of safely and efficiently delivering Cas9 ribonucleoprotein alone (termed NHEJ‐NP, diameter = 29.4 nm), or together with donor DNA (termed HDR‐NP, diameter = 33.3 nm) are reported. Moreover, intravenously, intratracheally, and intramuscularly injected NHEJ‐NP induces efficient gene editing in mouse liver, lung, and skeletal muscle, respectively. Intramuscularly injected HDR‐NP also leads to muscle strength recovery in a Duchenne muscular dystrophy mouse model. NHEJ‐NP and HDR‐NP possess many desirable properties including high payload loading content, small and uniform sizes, high editing efficiency, good biocompatibility, low immunogenicity, and ease of production, storage, and transport, making them great interest for various genome editing applications with clinical potentials.
- 28 April 2022
- Published by Wiley in Advanced Materials
- Vol. 34 (23) , 2110618-e2110618
pH‐Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA
Clustered regularly interspaced short palindromic repeat (CRISPR)‐associated protein 9 (Cas9) may offer new therapeutics for genetic diseases through gene disruption via nonhomologous end joining (NHEJ) or gene correction via homology‐directed repair (HDR). However, clinical translation of CRISPR technology is limited by the lack of safe and efficient delivery systems. Here, facilely fabricated pH‐responsive polymer nanoparticles capable of safely and efficiently delivering Cas9 ribonucleoprotein alone (termed NHEJ‐NP, diameter = 29.4 nm), or together with donor DNA (termed HDR‐NP, diameter = 33.3 nm) are reported. Moreover, intravenously, intratracheally, and intramuscularly injected NHEJ‐NP induces efficient gene editing in mouse liver, lung, and skeletal muscle, respectively. Intramuscularly injected HDR‐NP also leads to muscle strength recovery in a Duchenne muscular dystrophy mouse model. NHEJ‐NP and HDR‐NP possess many desirable properties including high payload loading content, small and uniform sizes, high editing efficiency, good biocompatibility, low immunogenicity, and ease of production, storage, and transport, making them great interest for various genome editing applications with clinical potentials.